Activity of irinotecan and temozolomide in the presence of O\(^6\)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models

W Cai\(^{1,2,5}\), NV Maldonado\(^1\), W Cui\(^1\), N Harutyunyan\(^1\), L Ji\(^{1,2,3}\), R Sposto\(^{1,2,3}\), CP Reynolds\(^{1,2,4,6}\) and N Keshelava\(^{6,1,2,4}\)

\(^{1}\)Division of Hematology-Oncology, MS#119, Children’s Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA; \(^{2}\)Department of Pediatrics, University of Southern California, Los Angeles, CA 90027, USA; \(^{3}\)Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA; \(^{4}\)Department of Pathology, University of Southern California, Los Angeles, CA 90027, USA; \(^{5}\)Current address: Cancer Center and Departments of Cell Biology and Biochemistry, Pediatrics, and Internal Medicine, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA; \(^{6}\)Current address: Department of Oncology, Department of Pediatric Surgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning 110004, PR China

**Background:** The combination of temozolomide (TMZ) and irinotecan is a regimen used in neuroblastoma patients with recurrent disease. O\(^6\)-methylguanine-DNA methyltransferase (MGMT) may have a function in resistance to TMZ. Using neuroblastoma preclinical models, we determined whether the inhibition of MGMT by O\(^6\)-benzylguanine (O6-BG) could enhance the anti-tumour activity of TMZ and irinotecan.

**Methods:** The cytotoxicity of TMZ and irinotecan, either alone or in combination, was measured in five neuroblastoma cell lines in the presence or absence of O6-BG with a fluorescence-based cell viability assay (DIMSCAN). Anti-tumour activity was measured in three neuroblastoma xenograft models.

**Results:** MGMT mRNA and protein were expressed in 9 out of 10 examined cell lines. Pretreatment of cells with 25 \(\mu\)M O6-BG decreased MGMT protein expression and enhanced the TMZ cytotoxicity by up to 0.3–1.4 logs in four out of five tested cell lines. TMZ (25 mg kg\(^{-1}\) per day for 5 days every 3 weeks for four cycles) did not significantly improve mouse survival, whereas the same schedule of irinotecan (7.5 mg kg\(^{-1}\) per day) significantly improved survival \((P<0.0001)\) in all three xenograft models. Combining O6-BG and/or TMZ with irinotecan further enhanced survival.

**Conclusion:** Our in vitro and in vivo findings suggest that irinotecan drives the activity of irinotecan and TMZ in recurrent neuroblastoma. Inhibitors of MGMT warrant further investigation for enhancing the activity of regimens that include TMZ.

British Journal of Cancer (2010) 103, 1369–1379. doi:10.1038/sj.bjc.6605927 www.bjcancer.com

**Published online 5 October 2010**

© 2010 Cancer Research UK

**Keywords:** active drug combinations; cytotoxicity; drug resistance; recurrent neuroblastoma

Neuroblastoma is the most common extracranial solid tumour of childhood. Myeloablative chemotherapy followed by hematopoietic stem-cell transplantation and then 13-cis retinoic acid (Matthay et al, 1999) or most recently anti-GD2 antibody and cytokines (Yu et al, 2009) improve survival of children with high-risk neuroblastoma, but many patients still die of progressive disease. Therefore, the development of new therapies is a priority.

Irinotecan, a topoisomerase I inhibitor, is a semi-synthetic water-soluble analogue of camptothecin, a pro-drug that undergoes de-esterification to an active metabolite, SN-38. Irinotecan, as a single agent, has shown activity in vitro (Keshelava et al, 2000) and in xenograft neuroblastoma models (Vassal et al, 1996; Thompson et al, 1997; Furman et al, 1999), and demonstrated some objective responses in neuroblastoma patients treated with various doses and schedules (Furman et al, 1999; Blaney et al, 2001; Kushner et al, 2005; Bomgaars et al, 2006, 2007). Preclinical data from rhabdomyosarcoma and neuroblastoma xenograft models have demonstrated schedule-dependent activity for irinotecan, with superior activity seen when using protracted low-dose administration (Houghton et al, 1995).

Temozolomide (TMZ), a DNA methylating imidazole tetrazine, inhibits cell growth in neuroblastoma xenografts (Middlemas et al, 2000) and has been shown to have activity in high-risk neuroblastoma patients (De et al, 2006; Rubie et al, 2006). It has been hypothesised that the cytotoxic activity of TMZ is mediated through reactive O\(^6\)-methylguanine in DNA (Tisdale, 1987); thus, inhibition of O\(^6\)-methylguanine-DNA methyltransferase (MGMT), a DNA repair protein at the O\(^6\)-guanine position, may increase the cytotoxicity of TMZ against neuroblastomas (Wagner et al, 2007b). O\(^6\)-benzylguanine (O6-BG)
irinotecan is a potent suppressor of MGMT activity, acting as a substrate for MGMT (Dolan et al, 1990). Irinotecan is commonly used in combination with TMZ to treat recurrent high-risk neuroblastomas (Wagner et al, 2009) because of their synergistic interaction in xenograft models (Houghton et al, 2000), and their activity in patients with Ewing sarcoma (Wagner et al, 2007a) and high-grade glioma (Reardon et al, 2005). Clinically, these agents are administered sequentially, starting with TMZ, because of the schedule-dependent activity demonstrated in xenograft models. It is presumed that the placement of an adduct at the O6 position of guanine by an alkylating agent, such as BCNU or TMZ, is critical for achieving synergistic activity with irinotecan (Castellino et al, 2000).

The purpose of the current study was to assess the activity of the TMZ and irinotecan combination in neuroblastoma pre-clinical models and to determine whether inhibition of MGMT by O6-BG significantly enhanced the anti-tumour activity of the combination.

MATERIALS AND METHODS

Drugs and chemicals
Both TMZ and O6-BG were obtained from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, National Cancer Institute (Bethesda, MD, USA). SN-38 was purchased from Abatra Technology Co., Ltd, and irinotecan was purchased from the pharmacy at Children’s Hospital Los Angeles. Fluorescein diacetate (FDA) was purchased from Eastman Kodak Company (Rochester, NY, USA), and eosin Y was from Sigma Chemical Co. (St Louis, MO, USA). Antibodies were purchased from various manufacturers: anti-MGMT monoclonal MT 3.1 Ab-1 from NeoMarkers (Fremont, CA, USA), caspase-3 (Cat# 9665) and phospho-H2AX (Ser 139, Cat# 9718) rabbit monoclonal antibody from Cell Signaling Technology (Danvers, MA, USA) and F7-26 from Chemicon International (Temecula, CA, USA).

Cell Lines
We used four drug-sensitive (SMS-SAN, CHLA-42, CHLA-15 and SMS-KCN), and seven multidrug-resistant (CHLA-171, CHLA-136, SK-N-RA, SK-N-BE(2), CHLA-90, CHLA-119 and CHLA-172) cell lines. CHLA-136 and SK-N-R cell lines carry wild type and transcriptionally active TP53 (Keshelava et al, 2001), SK-N-BE(2), CHLA-90, CHLA-119 and CHLA-172 carry mutant and transcriptionally inactive TP53 (Keshelava et al, 2001). CHLA-171 carries wild type, but transcriptionally inactive TP53, likely because of the MDM2 protein overexpression (Keshelava et al, 2001).

SMS-KCN cells were grown in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum (Omega Scientific, Tarzana, CA, USA). All other cells were grown in Iscove’s Modified Dulbecco’s Medium (Biowhittaker, Walkersville, MD, USA) supplemented with 20% fetal bovine serum, 3 mM l-Glutamine (Mediatech, Inc., Herndon, VA, USA) and 0.1% premium ITS culture supplement containing 5 μg ml⁻¹ insulin, 5 μg ml⁻¹ transferrin and 5 ng ml⁻¹ selenious acid (VWR Scientific, West Chester, PA, USA). The cell lines were cultured without antibiotics at 37°C in a humidified incubator containing 95% air and 5% CO₂ atmosphere. All cell lines tested negative for mycoplasma. Cell lines were confirmed by a short tandem repeat assay (Keshelava et al, 2001). SMS-KCN, CHLA-136 and CHLA-90 cell lines were tested in 12 replicate wells. Cell lines were incubated in the presence of these agents for 72 h, after which fluorescein diacetate was cytotoxic to neuroblastoma cells (Keshelava et al, 2001). A level that was cytotoxic to neuroblastoma cells (Keshelava et al, 2000). The clinically achievable level of TMZ in children is 13 ± 2.8 μg ml⁻¹ (Horton et al, 2007) and in xenograft models, TMZ C₅₀ is 36 μg ml⁻¹ (Houghton et al, 2000). Each drug concentration was tested in 12 replicate wells. Cell lines were incubated in the presence of these agents for 72 h, after which fluorescein diacetate was cytotoxic to neuroblastoma cells. In these experiments, TMZ was added to cells 3 h before irinotecan.

ssDNA damage measurements with F7-26 antibody
Cells were treated with O6-BG (25 μM, 24 h), TMZ (50 μg ml⁻¹, 6 h), SN-38 (20 ng ml⁻¹, 4 h) or their combinations, and analysed after overnight fixation in methanol – PBS (6:1). Staining with F7-26 monoclonal antibody was performed according to the manufacturer’s instructions. Flow cytometry was performed on a BD LSR II flow cytometer (BD Biosciences, San Jose, CA, USA) and data were acquired and analysed using BD FACSDiva software.

Immunoblot analysis of protein expression
Cells from three drug-sensitive cell lines (SMS-KCN, SMS-SAN and CHLA-42) and seven multidrug-resistant cell lines (CHLA-171,
CHLA-136, SK-N-RA, SK-N-BE(2), CHLA-90, CHLA-119 and CHLA-172 were grown to 70% confluence in 75 cm² flasks and then lysed in immunoprecipitation assay buffer (50 mM NaCl, 50 mM Tris (pH 7.4), 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulphate). Total protein (30 μg per lane) was fractionated on 10% tris-glycine precast gels (Pierce Biotechnology, Inc., Rockford, IL, USA), and protein: antibody complexes were detected by Pico chemiluminescent substrate (Pierce Biotechnology, Inc., Rockford, IL, USA), transferred to nitrocellulose membrane (Protran, Keene, NH, USA), and probed with primary antibodies at a 1: 1000 dilution, followed by incubation with an HRP-conjugated secondary antibody. The membranes were incubated with SuperSignal West Pico chemiluminescent substrate (Pierce Biotechnology, Inc., Rockford, IL, USA), and protein: antibody complexes were detected by autoradiography (Denville Scientific, Inc., Metuchen, NJ, USA). H2AX expression, phosphorylated at Ser 139, was assessed in CHLA-15 cells for characterisation of DNA double strand breaks. Similar doses and schedules were tested as with F7-26 monoclonal antibody staining.

**Animals**

Athymic (nu/nu) female mice, 6–7 weeks old (Harlan Laboratories, Inc., San Diego, CA, USA) were used in the study. Mice were housed in an air-conditioned room and fed the standard laboratory chow. All procedures were performed in compliance with the Children’s Hospital Los Angeles Institutional Animal Care and Use Committee-approved protocols.

**Mouse models of mass disease**

We used the SMS-KCNR, CHLA-136 and CHLA-119 neuroblastoma cell lines for the xenograft experiments. These cell lines were chosen to represent neuroblastomas that were: (a) drug-sensitive (SMS-KCNR), (b) multidrug-resistant with wild-type and transcriptionally active TP53 (CHLA-136) and (c) multidrug-resistant with mutant and transcriptionally inactive TP53 (CHLA-119) (Keshelava et al, 2001). Treatments began when tumours reached 200 mm³. Tumour measurements were made twice a week. Once tumour reached 1500 mm³, mice were humanely sacrificed.

**Treatment protocol**

Drugs were given as follows: O6-BG (30 mg kg⁻¹ delivered through intraperitoneal injections) was followed 1 h later by TMZ (25 mg kg⁻¹ given by oral gavage) and 1 h later by irinotecan (7.5 mg kg⁻¹ given by tail vein injection). O6-BG was dissolved in 4% DMSO, 30% PEG-400 and 66% saline, TMZ was dissolved in water, and irinotecan in saline. Control mice were administered sterile carrier solutions. Mice were treated on a 1-week on (5 days)-2 weeks off schedule for four cycles. The doses of administered drugs were chosen following determination of the maximum tolerated dose. The administered drugs at the doses reported here were well tolerated; no weight loss, diarrhea or abnormal behaviour was observed. White blood cell count was not monitored.

**Data analysis**

IC₉⁰ (drug concentrations that were cytotoxic or growth inhibitory for 90% of the cell population), and dose reduction index values were calculated using CalcuSyn software (Biosoft, Cambridge, UK) (Chou and Talalay, 1984).

The association between log-transformed RT-PCR values for MGMT RNA expression and immunoblot values for MGMT protein expression was assessed by calculating the Pearson’s correlation coefficient. All P-values were two-sided. The computations of the Pearson’s correlation coefficient were performed with the use of STATA software (version 9.0; College Station, TX, USA). A P-value of less than or equal to 0.05 was considered statistically significant.

**Figure 1** O³-methylguanine-DNA methyltransferase (MGMT) expression in drug-sensitive (white bars) and multidrug-resistant neuroblastoma cell lines (black bars). Lanes, 1 – SMS-SAN, 2 – CHLA-42, 3 – SMS-KCNR, 4 – CHLA-171, 5 – CHLA-136, 6 – SK-N-RA, 7 – SK-N-BE(2), 8 – CHLA-90, 9 – CHLA-119 and 10 – CHLA-172. (A) Quantification of mRNA expression for the MGMT gene by TaqMan reverse transcription–polymerase chain reaction in a panel of 10 neuroblastoma cell lines. Mean mRNA expression (normalised to GAPDH mRNA expression) and standard deviations (error bars) from three replicates are shown. (B) Upper panel: Immunoblot analysis of MGMT protein expression, equal protein loading was confirmed by immunoblot analysis of β-actin expression. Bottom panel: quantitative analysis of MGMT protein expression as a ratio to β-actin expression.
where $F_k$ is the mean fraction of logs of cell kill after treatment at the $j$th dose (0th, 1st, 2nd, 3rd and 4th drug conditions). The linear combination:

$$
\frac{1}{16} \times (F_{0j} - F_{0i}) + \frac{1}{8} \times (F_{1j} - F_{1i}) + \frac{3}{16} \times (F_{2j} - F_{2i}) + \frac{3}{8} \times (F_{3j} - F_{3i}) + \frac{1}{4} \times (F_{4j} - F_{4i})
$$

then tested the difference in treatment effects between two dose–response curves (designated as $i$ and $j$). Data were analysed with software SAS Version 9.1 (College Station, TX, USA).

For xenograft studies, the main effects of the three drugs (O6-BG, TMZ and irinotecan) on the length of survival of mice, as well as their second- and third-order interactions (e.g., enhancement of the effect of one drug with addition of another) were evaluated using censored regression models as implemented in the CNREG routine of STATA 9.0 (StataCorp LP, College Station, TX, USA). Days of survival were assumed to have a lognormal distribution, and the days were transformed to the natural log scale before analyses were carried out. O6-BG, TMZ and irinotecan, as well as their second- and third-order interaction terms were included in the initial regression model. For main drug effects, a $P$-value less than or equal to 0.05 was considered statistically significant. For test of interaction effect between drugs (e.g., enhancement in the effect of one drug with addition of another), a $P$-value less than or equal to 0.01 was considered statistically significant. $P$-values from likelihood ratio tests are presented. To compare the length of survival between any two groups of mice, a censored regression model was first fit using data from all the

![Graph showing fractional survival vs temozolomide and SN-38 combination in the presence of O6-methylguanine-DNA methyltransferase (MGMT) inhibitor in neuroblastoma cell lines obtained by DIMSCAN assay.](image)

**Figure 2** Effect of the temozolomide and SN-38 combination in the presence of O6-methylguanine-DNA methyltransferase (MGMT) inhibitor in neuroblastoma cell lines obtained by DIMSCAN assay. For MGMT inhibition, cells were pretreated with 25 $\mu$M O6-benzylguanine (O6-BG) for 24 h, temozolomide and/or SN-38 were then added for an additional 3 days. Dose–response curves for temozolomide alone (○), temozolomide in the presence of O6-BG (●), SN-38 alone (□), SN-38 in the presence of O6-BG (■), temozolomide and SN-38 (▲) and temozolomide and SN-38 in the presence of O6-BG (▼) were obtained by DIMSCAN assay.
treatment groups with the CNREG routine, then difference in mice survival between two treatment groups was evaluated by testing the appropriate linear combinations using the STATA LINCOM command. Data from the three cell lines was analysed separately. All P-values reported were two-sided.

RESULTS

MGMT RNA and protein expression

Around 10 neuroblastoma cell lines (SMS-SAN, SMS-KCN, CHLA-42, CHLA-171, CHLA-136, SK-N-RA, SK-N-BE(2), CHLA-90, CHLA-119 and CHLA-172) were tested for MGMT RNA and protein expression by TaqMan RT-PCR and immunoblotting, respectively (Figure 1A and B). All cell lines, except CHLA-90, expressed MGMT. MGMT RNA expression correlated significantly with MGMT protein expression ($r = 0.67$, $P < 0.03$). Thus, MGMT is expressed in neuroblastomas and may be a pharmacological target for therapeutic regimens that include TMZ, as previously suggested (Wagner et al., 2007b).

Cytotoxicity of O6-BG, TMZ and irinotecan in neuroblastoma cell lines

Next, we examined whether O6-BG can increase the activity of TMZ or the TMZ and irinotecan combination in neuroblastomas using three drug-sensitive (CHLA-15, CHLA-42 and SMS-KCN) and two multidrug-resistant (CHLA-90 and CHLA-136) cell lines, including the one that does not express MGMT (CHLA-90) (Figures 2 and 3). For these in vitro experiments, O6-BG was tested at 25 $\mu$M, a concentration chosen on the basis of the studies

![Figure 3: Cytotoxicity of sequentially or simultaneously administered temozolomide and SN-38 in neuroblastoma cell lines measured by the DIMSCAN assay. Cells were pretreated with 25 $\mu$M O6-benzylguanine (O6-BG) for 24 h, temozolomide and SN-38 were then added for an additional 3 days. Temozolomide was added 3 h before or simultaneously with SN-38. Dose–response curves for temozolomide and SN-38 administered simultaneously (▲), or sequentially (●) temozolomide and SN-38 administered simultaneously in the presence of O6-BG (▼), temozolomide + SN-38 administered sequentially in the presence of O6-BG (▼).](image-url)
Table 1  IC values for TMZ and SN-38, and DRI values for their combination in the absence or presence of O6-BG at the 90% growth inhibition

| Cell line   | IC90 TMZ (µM) | +O6-BG | IC90 SN-38 (ng ml⁻¹) | +O6-BG | TMZ (+SN38) | SN-38 (+TMZ) | DRIa | DRIo6-BG b |
|-------------|--------------|--------|----------------------|--------|-------------|-------------|------|------------|
| CHLA-15     | 31.2         | 7.2    | <2.5                 | <2.5   | >5.0        | ND          | ND   | ND         |
| CHLA-42     | >50a         | >50    | 14                   | 7.2    | >3.3        | 2.3         | >8   | >2.9       |
| SMS-KCNR    | 27.2         | <6.25  | <2.5                 | <2.5   | >4.3        | ND          | ND   | ND         |
| CHLA-136    | >50          | >50    | 6.7                  | 9.3    | >2          | 0.7         | >6.8 | 0.9        |
| CHLA-90     | >50          | >50    | >20                  | >20    | ND          | ND          | ND   | ND         |

Abbreviations: DRI = dose reduction index; IC90 = drug concentrations that were cytotoxic or growth inhibitory for 90% of the cell population; ND = not determined; O6-BG = O6-benzylguanine; TMZ = temozolomide. DRI reflects the fold reduction in the required concentration of tested agents when used in combination to achieve 90% cell death and/or growth inhibition. DRI for drugs determined in the presence of 25 µM O6-BG. IC90 values for temozolomide or SN-38 calculated in the presence of 25 µM O6-BG. DRI was not determined as over 90% cell death and/or growth inhibition was achieved by a single drug (SN-38 or TMZ) at the concentration that was lower (<2.5 ng ml⁻¹ or <6.25 µg ml⁻¹) than that tested. DRI was also not determined when 90% cell death and/or growth inhibition was not achieved at the tested concentrations, then the IC90 values were reported as ‘>’ the highest-tested concentration. The highest concentrations tested were: 50 µg ml⁻¹ for temozolomide and 20 ng ml⁻¹ for SN-38. Similarly, if 90% cell death and/or growth inhibition was achieved at the concentrations lower than that tested, then the IC90 values were reported as ‘<’ the lowest-tested concentration. The lowest concentrations tested were: 6.25 µg ml⁻¹ for temozolomide and 2.5 ng ml⁻¹ for SN-38.

Table 1

| Cell line   | IC90 TMZ (µM) | +O6-BG | IC90 SN-38 (ng ml⁻¹) | +O6-BG | TMZ (+SN38) | SN-38 (+TMZ) | DRIa | DRIo6-BG b |
|-------------|--------------|--------|----------------------|--------|-------------|-------------|------|------------|
| CHLA-15     | 31.2         | 7.2    | <2.5                 | <2.5   | >5.0        | ND          | ND   | ND         |
| CHLA-42     | >50a         | >50    | 14                   | 7.2    | >3.3        | 2.3         | >8   | >2.9       |
| SMS-KCNR    | 27.2         | <6.25  | <2.5                 | <2.5   | >4.3        | ND          | ND   | ND         |
| CHLA-136    | >50          | >50    | 6.7                  | 9.3    | >2          | 0.7         | >6.8 | 0.9        |
| CHLA-90     | >50          | >50    | >20                  | >20    | ND          | ND          | ND   | ND         |

Abbreviations: DRI = dose reduction index; IC90 = drug concentrations that were cytotoxic or growth inhibitory for 90% of the cell population; ND = not determined; O6-BG = O6-benzylguanine; TMZ = temozolomide. DRI reflects the fold reduction in the required concentration of tested agents when used in combination to achieve 90% cell death and/or growth inhibition. DRI for drugs determined in the presence of 25 µM O6-BG. IC90 values for temozolomide or SN-38 calculated in the presence of 25 µM O6-BG. DRI was not determined as over 90% cell death and/or growth inhibition was achieved by a single drug (SN-38 or TMZ) at the concentration that was lower (<2.5 ng ml⁻¹ or <6.25 µg ml⁻¹) than that tested. DRI was also not determined when 90% cell death and/or growth inhibition was not achieved at the tested concentrations, then the IC90 values were reported as ‘>’ the highest-tested concentration. The highest concentrations tested were: 50 µg ml⁻¹ for temozolomide and 20 ng ml⁻¹ for SN-38. Similarly, if 90% cell death and/or growth inhibition was achieved at the concentrations lower than that tested, then the IC90 values were reported as ‘<’ the lowest-tested concentration. The lowest concentrations tested were: 6.25 µg ml⁻¹ for temozolomide and 2.5 ng ml⁻¹ for SN-38.

Table 1

Demonstrating significant reduction of MGMT enzymatic activity in vitro by O6-BG at 10 µM (Bacoltd et al., 2002). Depletion of MGMT protein by 75 µM O6-BG has also been demonstrated (Murakami et al., 2007). Using western blotting, we confirmed reduced protein expression following treatment with 25 µM O6-BG in the SMS-KCNR and CHLA-136 cell lines (data not shown).

Figure 2 shows the dose–response curves obtained from the DIMSCAN assay. We calculated the concentrations that were growth inhibitory or cytotoxic for 90% of treated cells (IC90) for TMZ, SN-38 and TMZ and SN-38 in the presence or absence of O6-BG.

The single-agent IC90 values for TMZ ranged from 27 to >50 µg ml⁻¹ (Table 1). Addition of 25 µM O6-BG enhanced the growth inhibitory effect of TMZ by up to 1.4 logs in CHLA-15, 0.6 logs in CHLA-42, 0.9 logs in SMS-KCNR and 0.3 logs in CHLA-136 cells (Figure 2). The single-agent IC90 values for SN-38 ranged from <2.5 to >20 ng ml⁻¹ (Table 1). Addition of 25 µM O6-BG marginally enhanced growth inhibitory effect of SN-38 in the CHLA-42 cell line. The TMZ and SN-38 anti-neuroblastoma activity was tested at a fixed ratio of 2.5:1. The growth inhibitory activity of the combination was SN-38 driven in all tested lines. Addition of 25 µM O6-BG increased TMZ and SN-38-mediated growth inhibition by up to 0.6 logs in CHLA-42 and 0.5 logs in SMS-KCNR cell lines (Figure 2).

As TMZ is given before irinotecan to neuroblastoma patients, we examined whether administration of TMZ 3 h before SN-38 exposure would result in higher cytotoxicity in representative neuroblastoma cell lines: CHLA-15, SMS-KCNR and CHLA-90. Comparison of the dose–response curves of TMZ and SN-38 in the presence or absence of O6-BG, with the drugs administered simultaneously or sequentially, did not reach statistical significance (Figure 3).

DNA damage in vitro

Single- or double-strand (ss or ds) DNA breaks caused by the tested drugs and drug combinations were measured in a representative neuroblastoma cell line (CHLA-15), selected for its propensity to grow in single-cell suspension that does not clump excessively. F7-26 monoclonal antibody staining to single-stranded DNA was used to quantify ssDNA damage (Figure 4A and B). We have previously shown that this method distinguishes ssDNA breaks caused by exogenous stimuli from DNA strand breaks resulting from apoptosis (Grigoryan et al., 2007). Phosphorylation of the H2A histone variant, H2AX, at serine-139 was used to quantify dsDNA damage (Figure 4C).

SN-38-induced more prominent single-strand (4.3-fold higher F7-26 staining) or double-strand (84-fold higher expression of pS139-H2AX) DNA damage, compared with TMZ (ssDNA = two-fold, dsDNA = 11-fold) or O6-BG (ssDNA = 1 and dsDNA = 4). Significantly more ssDNA damage was achieved by any of the two drug combinations (O6-BG and TMZ, O6-BG + SN-38 and TMZ and SN-38). P-values < 0.001 relative to simple addition of single drug actions as measured by linear regression analysis. Synergistic induction of ssDNA breaks was not demonstrated for the triple drug combination. Thus, the data show that increased DNA damage by the two- and three-drug combinations results mostly from the breakage induced by SN-38, although TMZ and/or O6-BG further enhanced DNA breaks.

Activity in the mouse xenograft models

First, we confirmed that the planned dosing schedule achieved the desired pharmacodynamic effect on the xenograft tumours. SMS-KCNR mice were treated with O6-BG or and TMZ for 1 week and sacrificed. Tumour tissues were obtained and MGMT depletion by O6-BG was demonstrated by immunoblotting (Figure 5A), whereas induction of apoptosis was verified by cleavage of caspase 3 (Figure 5B).

Formal factorial design was applied to our xenograft studies for comprehensive assessment of contributions of single drugs or two-drug combinations to the anti-tumour activity obtainable by the O6-BG, TMZ and irinotecan combination (Table 2).

TMZ as a single agent did not have any significant effect on survival of either SMS-KCNR (P = 0.21), CHLA-136 (P = 0.81) or CHLA-119 (P = 0.9) xenografts; however, addition of O6-BG resulted in significant evidence of enhancement of TMZ effect in SMS-KCNR xenografts (P = 0.002). This enhancement was marginally significant in CHLA-119 (P = 0.018) xenografts.

O6-BG, as a single agent, significantly improved survival of the CHLA-136 xenografts (P = 0.007). When administered as single agents, TMZ and O6-BG did not show significant difference in mean survival days in SMS-KCNR (P = 0.29) or CHLA-119 (P = 0.032) xenografts, but showed significant difference in CHLA-136 (P = 0.018) xenografts.

Irinotecan delivered the most activity among the treated groups (Figure 6). As a single agent, irinotecan significantly improved the survival rate (P < 0.0001) in all three xenograft models. Addition of TMZ (Figure 6) or O6-BG did not significantly improve irinotecan activity. In contrast, addition of O6-BG to the TMZ and irinotecan combination significantly increased survival days of SMS-KCNR (P = 0.017), CHLA-136 (P = 0.033) and CHLA-119 (P = 0.017).
Figure 4  Assessment of single- and double-stranded DNA damage by O6-benzylguanine (O6-BG), temozolomide, irinotecan and their combinations in a representative neuroblastoma cell line. CHLA-15 cells were treated with O6-BG (25 μM, 24 h), temozolomide (TMZ, 50 μg ml⁻¹, 6 h), and SN-38 (20 ng ml⁻¹, 4 h). (A) Single-strand breaks were quantified by F7-26 monoclonal antibody using flow cytometric assay. Each condition was examined as three replicates. (B) Quantification of single-strand DNA breaks as measured by flow cytometry. Mean values and standard deviation were calculated from three replicates. (C) The marker of double-strand DNA-damage, H2AX phosphorylated at Ser 139 (15 kDa), was measured by immunoblotting. Equal protein loading was confirmed by immunoblot analysis of β-actin expression. Upper panel: immunoblot analysis of pH2AX expression. Bottom panel: quantitative analysis of pH2AX protein expression as a ratio to β-actin expression. Lanes: 1 – untreated controls, 2 – TMZ, 3 – SN-38, 4 – O6-BG, 5 – TMZ and SN-38, 6 – TMZ and O6-BG, 7 – SN-38 and O6-BG and 8 – Triple.
Human neuroblastoma cell lines SMS-KCNR, CHLA-119 and CHLA-136 were established as s.c. xenografts in nu/nu mice. Animals received O6-benzylguanine (O6-BG, 30 mg kg\(^{-1}\)) followed 1 h later by temozolomide (TMZ, 25 mg kg\(^{-1}\)) and 1 h later by irinotecan (IRN, 7.5 mg kg\(^{-1}\)). Control mice were administered sterile carrier solutions. Mice were treated for 5 days every 3 weeks for four cycles. Animals were sacrificed when tumours reached 1500 mm\(^3\). Survival probability of mice treated with vehicle control (pink lines), O6-BG and TMZ (gray lines), IRN (green lines), TMZ and IRN (blue lines), O6-BG, TMZ and IRN (red lines) are shown.

**Table 2** Survival of neuroblastoma xenografts in response to TMZ and/or IRN in the presence or absence of O6-BG

| Treatment                  | N\(^{a}\) | Mean days\(^b\) (95% CI\(^{c}\)) | N | Mean days (95% CI) | N | Mean days (95% CI) |
|---------------------------|---------|-------------------------------|---|-------------------|---|-------------------|
| Control                   | 10\(^{d}\) | 16.6 (11.9, 23.3)             | 11 | 20.7 (14.9, 28.8) | 10 | 29.7 (23.3, 37.3) |
| O6-BG                     | 5       | 19.3 (13.2, 27.9)             | 6  | 32.8 (25.4, 42.9) | 5  | 25.0 (18.3, 34.8) |
| TMZ                       | 5       | 16.0 (11.4, 22.4)             | 5  | 21.3 (13.6, 33.1) | 5  | 37.7 (10.9, 131.6) |
| IRN                       | 5       | 100.5 (85.6, 119.1)           | 5  | 146.9 (86.6, 249.1)| 5  | 239.2 (166.3, 344.2)|
| O6-BG+TMZ                 | 5       | 45.6 (35.2, 59.7)             | 6  | 27.7 (18.4, 41.7) | 5  | 53.5 (46.1, 62.2) |
| O6-BG+IRN                 | 5       | 100.5 (83.9, 120.3)           | 5  | 121.5 (108.9, 134.3)| 4  | 215.3 (131.6, 352.3)|
| TMZ+IRN                   | 10      | 135.2 (109.9, 144.4)          | 11 | 122.7 (113.3, 131.6)| 5  | 181.3 (121.5, 270.4)|
| Triple                    | 5       | 186.2 (119.8, 289.6)          | 6  | 173.5 (132.8, 226.8)| 5  | 361.4 (198.1, 659.4)|

Abbreviations: IRN = irinotecan; O6-BG = O6-benzylguanine; TMZ = temozolomide. *Number of mice evaluated. **Geometric average day for tumours to reach 1500 mm\(^3\). The mean survival days and 95% confidence intervals take into account the censored mice (those that were alive at the last follow-up date and did not have tumour equal or above 1500 mm\(^3\)). The maximum likelihood analysis was used to perform calculations (http://www.webull.com/lifeDataWeb/analysis_parameter_methods.htm). cConfidence intervals. dExperiments for each xenograft line were split in two parts conducted in short succession (1 – 2 months apart) and, therefore, two sets of the control mice were used for each xenograft. The combination of temozolomide and irinotecan was tested twice in SMS-KCNR and CHLA-136 xenografts to confirm the reproducibility of our findings in the models.

**DISCUSSION**

The combination of TMZ, a DNA methylating agent, with irinotecan, a topoisomerase I inhibitor, had emerged as a promising regimen for recurrent neuroblastoma (Kushner et al, 2006; Wagner et al, 2009). However, recent evidence suggests that the effectiveness of TMZ in neuroblastomas can be diminished by MGMT-mediated DNA damage repair (Middlemas et al, 2000; Wagner et al, 2007b). MGMT is frequently expressed in neuroblastoma tumours and cell lines (Middlemas et al, 2000; Wagner et al, 2007b). MGMT methylation in the promoter region has also been examined in neuroblastomas as promoter hypermethylation is associated with decreased MGMT expression. In those studies, promoter hypermethylation ranged from 0 to 27% in the examined tumours and cell lines (Harada et al, 2002; Gonzalez-Gomez et al, 2003; Lazcoz et al, 2007). Depletion of MGMT activity by the selective inhibitor, O6-BG, reportedly enhanced the cytotoxicity of TMZ in human brain tumour (Bobola et al, 1996) and melanoma (Wedge et al, 1997) xenografts. O6-BG also enhanced the anti-tumour activity of the TMZ and irinotecan combination in a model of disseminated neuroblastoma (Wagner et al, 2007b) and glioma xenograft models (Friedman et al, 2002).

**Figure 5** Assessment of pharmacodynamic markers of O\(^{6}\)-benzylguanine (O6-BG) and temozolomide activity. (A) SMS-KCNR cells were established as subcutaneous (s.c.) xenografts in nu/nu mice. Expression of O\(^{6}\)-methylguanine-DNA methyltransferase was determined in tumour tissue following 5 days of administration of O6-BG at 30 mg kg\(^{-1}\) each day. (B) Pro-caspase 3 (35 kDa) and cleaved caspase 3 (19 and 17 kDa) were measured by immunoblotting in tumour tissues of SMS-KCNR xenografts after daily administration of O6-BG and/or temozolomide (25 mg kg\(^{-1}\)) for 5 days. Lanes: 1 – controls, 2 – mice treated with O6-BG, 3 – mice treated with temozolomide, 4 – mice treated with the combination of O-BG and temozolomide. Equal protein loading was confirmed by immunoblot analysis of \(\beta\)-actin expression.

**Figure 6** Human neuroblastoma cell lines SMS-KCNR, CHLA-119 and CHLA-136 were established as s.c. xenografts in nu/nu mice. Animals received O\(^{6}\)-benzylguanine (O6-BG, 30 mg kg\(^{-1}\)) followed 1 h later by temozolomide (TMZ, 25 mg kg\(^{-1}\)) and 1 h later by irinotecan (IRN, 7.5 mg kg\(^{-1}\)). Control mice were administered sterile carrier solutions. Mice were treated for 5 days every 3 weeks for four cycles. Animals were sacrificed when tumours reached 1500 mm\(^3\). Survival probability of mice treated with vehicle control (pink lines), O6-BG and TMZ (gray lines), IRN (green lines), TMZ and IRN (blue lines), O6-BG, TMZ and IRN (red lines) are shown.
We undertook this large-scale study to formally assess the anti-
tumour activities of O6-BG, TMZ and irinotecan, as well as their second- and third-order interactions (such as enhancement of one-
drug effect with addition of another) in neuroblastoma pre-clinical
models. To our knowledge, such extensive assessment has not been
carried out previously.

In our study, 10 neuroblastoma cell lines were examined for
MGMT RNA and protein expression. All expressed MGMT, except the multidrug-resistant cell line, CHLA-90, which carries a
TP53 mutation (Keshelava et al., 2001). This is consistent with a
report showing that promoter methylation of the MGMT gene (which results in low or absent MGMT expression) is
associated with an increased frequency of TP53 mutations
(Nakamura et al., 2001).

We have evaluated the anti-neuroblastoma activity of O6-BG,
TMZ and irinotecan in vitro and in vivo. Drug levels used for
O6-BG decreased MGMT protein expression both in vitro (data not
shown) and in vivo (Figure 5A). Our in vitro data confirmed that
O6-BG enhanced the cell sensitivity to TMZ. Pre-treatment with
25 μM O6-BG sensitised four out of the five tested neuroblastoma
cell lines to TMZ by 0.3–1.4 logs (Figure 2); sensitising effect was
not demonstrated in the highly drug-resistant CHLA-90 cells that
lack MGMT expression. In xenografts, O6-BG as a single agent had
a significant effect on the survival of CHLA-136 tumour-bearing
mice (P = 0.007). O6-BG significantly enhanced TMZ activity in
SMS-KCNR (P = 0.002) and marginally in CHLA-119 (P = 0.018)
mice.

Temozolomide, either alone (Rubie et al., 2006) or in combina-
tion with irinotecan (Wagner et al., 2009), is being actively
investigated as a possible first-line regimen for recurrent
neuroblastomas. In our study, single agent TMZ did not have a
significant effect on the survival of either SMS-KCNR, CHLA-136
or CHLA-119 xenografts at the administered dose and schedule. We carefully selected the drug levels for our in vitro
(0–50 μg ml⁻¹) and xenograft experiments (25 mg kg⁻¹ per day),
on the basis of the previously reported pre-clinical and clinical
pharmacokinetic data of TMZ. The pharmacokinetic studies by
Stevens et al., and Houghton et al., conducted in mice, demon-
strated that oral administration of 20 mg kg⁻¹ or 66 mg kg⁻¹
temozolomide resulted in a Cmax of 19.6 μg ml⁻¹ (Stevens et al.,
1987) or 36 μg ml⁻¹ (Houghton et al., 2000), respectively. The
TMZ Cmax levels achievable in children are in the range of
5.6 ± 1.8 μg ml⁻¹ (Baruchel et al., 2006) to 13 ± 2.8 μg ml⁻¹ (Horton
et al., 2007). Thus, administration of 25 mg kg⁻¹ per day TMZ in
mice would result in a systemic exposure well within the clinically
relevant drug levels. By demonstrating caspase 3 activation, a
hallmark of apoptosis (Figure 3B), in SMS-KCNR xenografts, we
confirmed the suitability of the administered drug dose.

Irinotecan, as a single-agent, had substantial activity in vitro in
four neuroblastoma cell lines, achieving 1.1–2.8-log cytotoxicity at
20 ng ml⁻¹ (achievable in patients, Vassal et al., 2003), and in our
xenograft models. Our results are in agreement with other pre-
clinical investigations of irinotecan that demonstrated activity
against neuroblastomas (Komuro et al., 1994; Vassal et al., 1996;
Thliveris et al., 1999; Witterman et al., 1999). However, phase II
clinical trials of single-agent irinotecan have only shown limited
activity in neuroblastoma patients (Bomgaard et al., 2007; Vassal
et al., 2008). Such divergence could be attributed to the disparate
metabolism of irinotecan into its active metabolite SN-38 in different species. It is estimated that mouse liver and kidney
carboxylesterase more actively hydrolyses irinotecan than either
human carboxylesterase (hCE1) (173 vs 2.5 pmol mg⁻¹ min⁻¹
activity) (Xie et al., 2003) or hCE2, a more potent activator of
irinotecan than human carboxylesterase1 (Humerickhouse et al.,
2000). Nonetheless, the strong anti-neuroblastoma activity
achieved by irinotecan in all our three xenograft models warrants
further testing of irinotecan with additional agents to identify
synergistic combinations against recurrent neuroblastomas.

In contrast to previous pre-clinical investigations of TMZ
and irinotecan in neuroblastoma xenograft models (Houghton
et al., 2000), our studies did not demonstrate synergy between
these drugs. The difference may be attributable to the use in
the studies by Houghton et al. of dose levels of irinotecan and
TMZ that were unlikely to induce complete responses when administered alone. In our study, standardised dose-
schedule for irinotecan and TMZ were used to mimic the
clinical application of O6-BG, TMZ and irinotecan in children.
In addition, the 5-day schedule for irinotecan instead of the
(dx5(x2)) schedule used by Houghton et al. may have also contributed to the different responses seen in these two pre-clinical studies.

Previous studies have examined the effect of O6-BG on the
anti-tumour activity of the TMZ and irinotecan combination in
neuroblastomas (Wagner et al., 2007b) and in gliomas
(Friedman et al., 2002; Quinn et al., 2009). A recent phase I clinical
trial in adults with recurrent malignant glioma evaluated the
combination of O6-BG, TMZ and irinotecan, administered once
on 21-day schedule (Quinn et al., 2009). Although the primary
goal of the study was to define the maximum tolerated dose and
dose-limiting toxicity of the evaluated drugs, it did not demon-
strate any responses. The lack of responses was hypothesized to be
due to subtherapeutic doses or timing of administered doses. Our in vivo studies, conducted in a mouse model of mass
disease, demonstrated significantly improved survival for xen-
ografts treated with the TMZ and irinotecan combination in the
presence of O6-BG, in agreement with the findings by Wagner et al. in a mouse model of metastatic disease (Wagner et al., 2007b).

Our data suggest that the enhanced anti-neuroblastoma activity
by the triple combination resulted from significant irinotecan
activity together with the added benefit of statistically signifi-
cant O6-BG (in CHLA-136) or O6-BG and TMZ (in SMS-KCNR
and CHLA-119) activities. This is confirmed by the DNA studies
where single- or double-stranded DNA damage was mostly
due to SN-38 and further enhanced with the addition of TMZ and/or O6-BG, emphasising the critical cytotoxic effect of
irinotecan in the combination. Moreover, we observed improved
survival at 400 days of the multidrug-resistant xenograft
CHLA-119 in contrast to the study by Wagner et al., in which
the apparent advantage of adding O6-BG to TMZ and irinotecan
seen at 180 days was lost at 300 days. The difference between
these two studies can be explained by the use of four cycles of
therapy in our study rather than two as employed by Wagner
et al., or it may be attributable to the utilisation of the different
strain of mice.

Our extensive in vitro and in vivo investigations using formal
factorial design allowed us to convincingly demonstrate in
neuroblastoma pre-clinical models that (a) irinotecan adminis-
tered on a protracted schedule has remarkable anti-tumour
activity; (b) MGMT inhibition enhances the anti-tumour activity
of TMZ, confirming MGMT as a relevant pharmacological target.
These data suggest that inhibition of MGMT should be further
investigated especially in regimens containing TMZ and identifica-
tion of new drug combinations for irinotecan are warranted for
the treatment of high-risk neuroblastomas.

ACKNOWLEDGEMENTS

The authors thank Tsen-Yin (Jackie) Lin and Michael A Sheard for
their help with flow cytometry analysis, Martine Torres for her
critical review of the paper. This work was supported in part by
awards from the National Cancer Institute, CA081403 and
CA82830, and by the Neil Bogart Memorial Laboratories of
the Tj Martell Foundation for Leukemia, Cancer and AIDS
Research.
REFERENCES

Bacolod MD, Johnson SP, li-Osman F, Modrich P, Bullock NS, Colvin OM, Bigner DD, Friedman HS (2002) Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma. Mol Cancer Ther 1: 727–736.

Baruchel S, Diezi M, Hargrave D, Stempak D, Gammon J, Moghabi A, Coppers MJ, Fernandez CV, Bouffet E (2006) Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 42: 2335–2342.

Blaney S, Berg SL, Pratt C, Weilman S, Sullivan J, Luchtman-Jones L, Bernstein M (2001) A phase I study of irinotecan in pediatric patients. Cancer Chemother Pharmacol 47: 32–37.

Bobola MS, Tseng SH, Blank A, Berger MS, Silber JR (1996) Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozocin. Clin Cancer Res 2: 735–741.

Bomgaars L, Kerr J, Berg S, Kuttles J, Klenke R, Blaney SM (2006) A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer 46: 50–55.

Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, Adamson PC, Blaney SM (2007) Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 25: 4622–4627.

Castellino RC, Elion GB, Keir ST, Houghton PJ, Johnson SP, Bigner DD, Bomgaars LR, Kerr J, Berg S, Kuttesch J, Klenke R, Blaney SM (2006) A phase I study of irinotecan in pediatric patients. Cancer Chemother Pharmacol 45: 345–349.

Chou TC, Talalay P (1984) Quantitative-analysis of dose-effect relationships – the combined effects of multiple-drugs or enzyme-inhibitors. Adv Enzyme Regul 22: 27–55.

De SL, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A (2006) Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer 47: 30–36.

Dolan ME, Moschel RC, Pegg AE (1990) Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 87: 5368–5372.

Frgala T, Kalous O, Proffitt RT, Reynolds CP (2007) A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 6: 866–877.

Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC, Bigner DD, Dolan ME (2002) O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther 1: 943–948.

Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ (1999) Direct translation of a protracted irinotecan schedule of temozolomide using the F7-26 monoclonal antibody. Cancer Chemother Pharmacol 45: 679–688.

Gonzalez-Gomez P, Bello MJ, Lomas J, Arjona D, Alonso ME, Aminoso C, Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC, Frgala T, Kalous O, Proffitt RT, Reynolds CP (2005) DIMSCAN: a microfluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 110: 139–153.

Houghton NJ, Frohlich K, Krejsa J, Kalous O, Reynolds CP (2005) Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol 55: 1–8.

Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP (2001) Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 61: 6185–6193.

Komuro H, Li P, Tsachida Y, Yokomori K, Nakajima K, Aoyama T, Taneko M, Kaneda N (1994) Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma. Pediatr Oncol 23: 487–492.

Kushner BH, Kramer K, Modak S, Cheung NK (2005) Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma. Cancer 103: 858–862.

Kushner BH, Kramer K, Modak S, Cheung NK (2006) Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 24: 5271–5276.

Lazcos P, Munoz J, Nistal M, Pestana A, Encio IJ, Castresana JS (2007) Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma. Cancer Genet Cytoenet 174: 1–8.

Ma MK, Zamboni WC, Radomski RM, Furman WL, Santana VM, Houghton PJ, Hanna SK, Smith AK, Stewart CF (2000) Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res 6: 813–819.

Masters JR, Thompson SA, Daly-BURNS B, Reid YA, Dirks WG, Packer P, Toji LH, Ohno T, Tanabe H, Arleff CF, Kelland LR, Harrison M, Virmani A, Ward TH, Ayres KL, Debenham PG (2001) Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 98: 8012–8017.

Matthay KK, Villablanca JG, Seeger RC, Tram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemo-therapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 341: 1165–1173.

Middlemas DL, Stewart CF, Kirstein MN, Poquette C, Friedman HS, Houghton PJ, Brent TP (2000) Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 6: 998–1007.

Murakami M, Lee YJ, Kokeguchi S, Tsujigiwa H, Asaumi J, Nagatsuka H, Fukui K, Kuroda M, Tanaka N, Matsubara N (2007) Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cells. Oncol Rep 17: 1461–1467.

Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G-C→A T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22: 1715–1719.

Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Gurrungarun S, Sampson JH, McLendon RE, Herndon JE, Friedman HS (2009) Phase I trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer 115: 2964–2970.

Reardon DA, Quinn JA, Rich NJ, Desjardins A, Vredenburgh JJ, Gurrungarun S, Sathornsumetee S, Bradruddja M, McLendon R, Provenzale J, Herndon JE, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS (2005) Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104: 1478–1486.

Rubie H, Chisholm J, Defachelles AS, Morland B, Munzer C, Valteau-Couanet D, Mosseri V, Bergeron C, Weston C, Coze C, Waidyaratne SN, Luna MC, Murakami M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G-C→A T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22: 1715–1719.
Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846–5852

Thompson J, Zamboni WC, Cheshire PJ, Lutz L, Luo X, Li Y, Houghton JA, Stewart CF, Houghton PJ (1997) Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 3: 423–431

Tisdale MJ (1987) Antitumor imidazotetrazines – XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 36: 457–462

Vassal G, Doz F, Frappaz D, Imadalou K, Sicard E, Santos A, O’Quigley J, Germa C, Risse ML, Mignard D, Pein F (2003) A phase I study of irinotecan as a three-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 21: 3844–3852

Vassal G, Giammarile F, Brooks M, Geoerger B, Couanet D, Michon J, Stockdale E, Schell M, Geoffray A, Gentet JC, Pichon F, Rubie H, Cisar L, Assadourian S, Morland B (2008) A Phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Societe Francaise d’Oncologie Pediatricque (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur J Cancer 44: 2453–2460

Vassal G, Terrier-Lacombe MJ, Bissery MC, Venuat AM, Gerygaly F, Benard J, Morize J, Boland I, Ardoun P, Bressac-de-Paillerets B, Gouyette A (1996) Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 74: 537–545

Wagner LM, McAllister N, Goldsby RE, Rausen AR, Nall-Knapp RY, McCarville MB, Allbritton K (2007a) Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 48: 132–139

Wagner LM, McLendon RE, Yoon KJ, Weiss BD, Billups CA, Danks MK (2007b) Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clin Cancer Res 13: 5418–5425

Wagner LM, Villablanca JC, Stewart CF, Crews KR, Grosvenor S, Reynolds CP, Park JR, Maris JM, Hawkins RA, drug-Link HE, Jackson HA, Matthay KK (2009) Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol 27: 1290–1296

Wedge SR, Porteous JR, Newlands ES (1997) Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 40: 266–272

Xie M, Yang D, Wu M, Xue B, Yan B (2003) Mouse liver and kidney carboxylesterase (M-LK) rapidly hydrolyzes antitumor prodrug irinotecan and the N-terminal three quarter sequence determines substrate selectivity. Drug Metab Dispos 31: 21–27

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman S, Chen HX, Matthay KK, Cohn SL, Maris JM, Sondel P (2009) A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children’s Oncology Group (COG) study ANBL0032. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 27:15s (abstract)